Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity
Martin Friedrichsen, Lars Endahl, Frederik Flindt Kreiner, et al.
Molecular Metabolism (2023) Vol. 78, pp. 101801-101801
Open Access | Times Cited: 24

Showing 24 citing articles:

A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
Arun J. Sanyal, Pierre Bédossa, Mandy Fraessdorf, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 4, pp. 311-319
Open Access | Times Cited: 123
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
Carel W. le Roux, Oren Steen, Kathryn Jean Lucas, et al.
The Lancet Diabetes & Endocrinology (2024) Vol. 12, Iss. 3, pp. 162-173
Closed Access | Times Cited: 67
Transforming obesity: The advancement of multi-receptor drugs
Christine M. Kusminski, Diego Pérez–Tilve, Timo D. Müller, et al.
Cell (2024) Vol. 187, Iss. 15, pp. 3829-3853
Closed Access | Times Cited: 24
A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity
Linong Ji, Hongwei� Jiang, Zhi-Feng Cheng, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 29
Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
Bo Zhang, Zhifeng Cheng, Ji Chen, et al.
Diabetes Care (2023) Vol. 47, Iss. 1, pp. 160-168
Open Access | Times Cited: 22
NK2R control of energy expenditure and feeding to treat metabolic diseases
Frederike Sass, Tao Ma, Jeppe H. Ekberg, et al.
Nature (2024) Vol. 635, Iss. 8040, pp. 987-1000
Open Access | Times Cited: 9
Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity
Jonathan Brix Winther, Jens J. Holst
Diabetes Obesity and Metabolism (2024)
Open Access | Times Cited: 6
The dual GCGR/GLP‐1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection
Leo Thomas, Eric Martel, Wolfgang Rist, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 6, pp. 2368-2378
Open Access | Times Cited: 5
The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines
Sten Madsbad, Jens J. Holst
Expert Opinion on Investigational Drugs (2025), pp. 1-19
Open Access
Treat metabolic diseases with effective and approved therapies while new treatments are under investigation
Aisling McGuigan
Drugs & Therapy Perspectives (2025)
Closed Access
Antifibrotic Therapies for Metabolic Dysfunction-associated Steatotic Liver Disease
Robert F. Schwabe, Frank Tacke, Atsushi Sugimoto, et al.
JHEP Reports (2025), pp. 101421-101421
Open Access
Oxyntomodulin-past, present and future
Jens J. Holst, Mette M. Rosenkilde
Peptides (2025), pp. 171393-171393
Closed Access
Adaptive infusion of a glucagon‐like peptide‐1/glucagon receptor co‐agonist G3215, in adults with overweight or obesity: Results from a phase 1 randomized clinical trial
David C. D. Hope, Saleem Ansari, Sirazum Choudhury, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 4, pp. 1479-1491
Open Access | Times Cited: 3
Glucagon-based therapy for people with diabetes and obesity: What is the sweet spot?
Emma Rose McGlone, Tricia Tan
Peptides (2024) Vol. 176, pp. 171219-171219
Open Access | Times Cited: 2
Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges
C. Allard, Daniela Cota, Carmelo Quarta
Drugs (2023) Vol. 84, Iss. 2, pp. 127-148
Closed Access | Times Cited: 6
OXM-104, a potential candidate for the treatment of obesity, NASH and type 2 diabetes
Simone Anna Melander, Ashref Kayed, Kim Vietz Andreassen, et al.
European Journal of Pharmacology (2023) Vol. 962, pp. 176215-176215
Open Access | Times Cited: 6
Polyagonists in Type 2 Diabetes Management
Harsha Dissanayake, N. P. Somasundaram
Current Diabetes Reports (2023) Vol. 24, Iss. 1, pp. 1-12
Closed Access | Times Cited: 5
The effects of Fc fusion protein glucagon-like peptide-1 and glucagon dual receptor agonist with different receptor selectivity in vivo studies
Peng Jiang, Ying Zeng, Wen Yang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 174, pp. 116485-116485
Open Access | Times Cited: 1
Phenylpiracetam: molecular mechanisms of effects in obesity
О. А. Громова, I. Yu. Torshin, Л. Б. Лазебник
Meditsinskiy sovet = Medical Council (2024), Iss. 6, pp. 124-131
Open Access | Times Cited: 1
Chemoreactomic study of fonturacetam effects: molecular mechanisms of influence on adipose tissue metabolism
О. А. Громова, I. Yu. Torshin
FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology (2024) Vol. 17, Iss. 2, pp. 172-181
Open Access | Times Cited: 1
Incretin hormone agonists: Current and emerging pharmacotherapy for obesity management
Ibrahim S. Alhomoud, Azita H. Talasaz, Preethi Chandrasekaran, et al.
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (2024) Vol. 44, Iss. 9, pp. 738-752
Closed Access | Times Cited: 1
Methods of machine learning and big data analysis to establish the molecular mechanisms of the effects of racetams on the metabolism of adipose tissue
I. Yu. Torshin, О. А. Громова, Л. Б. Лазебник
Experimental and Clinical Gastroenterology (2024), Iss. 5, pp. 12-25
Open Access
Oxyntomodulin physiology and its therapeutic development in obesity and associated complications
Martin Tze Wah Kueh, Ming Chuen Chong, Alexander D. Miras, et al.
The Journal of Physiology (2024)
Open Access
Multi‐target Peptides for the Treatment of Metabolic Diseases
Martin Bossart, Gerhard Heßler
(2024), pp. 269-288
Closed Access
Page 1

Scroll to top